Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congressdescribe mechanistic insights for greater potency with verekitug compared to tezepelumab –
– Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) –
WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin (TSLP) receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress taking place June 13-16, 2025, in Glasgow, United Kingdom.
TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective treatment approach. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. Upstream is developing verekitug in multiple severe respiratory diseases including severe asthma, COPD, and CRSwNP. Verekitug is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor.
'These data reinforce our belief in the differentiated profile of verekitug, as the model elucidates important biologic parameters that drive the differentiated rapid, substantial and sustained treatment effects observed through TSLP receptor inhibition with verekitug,' said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development of Upstream Bio. 'We look forward to further assessing the potential translation of this unique mechanism into clinical benefit in patients with severe respiratory diseases, first with top-line Phase 2 clinical data in CRSwNP in the third quarter of this year followed by data in severe asthma in the first half of 2026.'
Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows:
A digital version of the presentation can be found on the Upstream Bio website.
About TSLP and TSLPR Blockade
Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy.
TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (TSLPR) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases.
About Verekitug
Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. Verekitug is currently being evaluated in two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials, the VALIANT trial in patients with severe asthma (NCT06196879) and the VIBRANT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT06164704). Upstream Bio is also initiating a Phase 2 clinical trial (NCT06981078) of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation.
Three clinical trials have been completed for verekitug, including a Phase 1 single-ascending dose (SAD) clinical trial and a Phase 1b multiple-ascending dose (MAD) clinical trial. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent pharmacokinetic profile and high subcutaneous bioavailability.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit www.upstreambio.com.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'continue,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'predict,' 'project,' 'seeks,' 'should,' 'target,' 'will' and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; expectations for future discussions with regulatory authorities and the potential of the endpoints of the Company's clinical trials to produce data that could support submissions for product approval; expectations regarding the differentiation, safety, efficacy or tolerability of verekitug; expectations regarding the translation of pharmacology modeling data of verekitug to clinical effects; and assessments comparing non-head-to-head clinical data of verekitug to published data for tezepelumab. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio's ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio's ability to fund its development activities and achieve development goals; Upstream Bio's dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio's ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio's financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio's competitors and industry; and other risks and uncertainties described in greater detail under the caption 'Risk Factors' in Upstream Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio's views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations [email protected]

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

26 minutes ago

• Bloomberg

Irish Regulator Warns Against Caving to Pressure on Bank Rules

Ireland's top banking supervisor warned of a need to stick with high standards of financial regulation particularly now when there is increasing pressure to ease them amid trade wars, geopolitical tensions and fears for global growth. 'If we're trying to chase growth with a deregulation engine I don't think that's going to end well for anybody,' Mary-Elizabeth McMunn, Deputy Governor for Financial Regulation at the Central Bank of Ireland, said at Bloomberg's Future of Finance event in Dublin. 'It also can't be that you simplify things just to such a degree that you really fail to capture complex risks.'

Forbes

40 minutes ago

• Forbes

'Waiting for A Miracle' In Bordeaux. Demand Is Down And So Are Prices.

SAINT EMILION, FRANCE - AUGUST 22: Replica of Bordeaux bottles are seen in a shop August 22, 2003 ... More in Saint Emilion outside Bordeaux. (Photo by Pascal)Winemaking in Bordeaux is never easy, even in the best of years, yet the region's promoters always seem to find a silver lining even in weak vintages. So the title 'Waiting for a Miracle' of a two-part survey by Wine Lister, a business consultant to the fine wine business, laced with phrases like 'crossing the Red Sea,' 'stormy weather,' 'a difficult situation' and 'turning point' comes as something of a shock at a time when the on-again-off-again Trump tariffs have added tremendous uncertainty to an industry based on grapevines that pay more attention to the weather than to international trade negotiations. Founder and CEO Ella Lister of industry consulting firm Wine Lister Compiled by Founder and CEO Ella Lister, Head of Clients and Marketing Tara Albini and Head of Analysyis Maggie Haan, Wine Lister does indicate that the 'murmurs of poor weather conditions and compromised fruit circulating nearly a year ago' were blunted by 'meticulous attention to detail in the vineyard and winery, coupled with unrivalled technology' that 'averted a disaster.' Declaring that 2024 was a very good year for dry whites and several reds, newly released wines are now more attractively priced, with discounts on the 2023 vintage in the UK down 20% to 30%, along with reduced volume ––this at a time of a worldwide wine glut. French wine and spirits global exports fell 4% last year and a 30% drop in sales volume is expected this year. At auction volumes also fell overall (38%). Quality scores for almost all 2024 Bordeaux dropped according to Wine Lister. Wine Lister's critics tasted en primeur Bordeaux over a nine-day period to find the wines to be 'restrained and vertical in nature, usually balanced, though sometimes austere,' with just 20 wines out of 134 recording an increase in scores. The top rated red wine was Château Latour with a score of 95.75 (out of 100), despite being down 1.5 points vs 2023. Among the top three risers are white wines, with La Mission Haut-Brion Blanc at the top. The silver lining in 2024 was low alcohol levels caused by cooler weather conditions, with wines often at around 13% ABV or lower, in contrast to growing levels of an increasing number of hot weather vintages. The wines of Saint-Émilion saw the steepest drop. 'Nonetheless, trade sentiment has been somewhat apathetic,' read the report, 'with consumers tightening their purse strings and choosing not to buy despite several wines sitting significantly below current market prices for back vintages.' The report also takes note that young people, pretty much worldwide, are 'largely disengaged,' a trend the industry is struggling to account for and reverse and it will take 'a concerted effort from all stakeholders––producers, the trade, and consumers alike–– to ensure Bordeaux retains its prestige and relevance in the modern fine Prices have dropped for the 2024 vintage. wine landscape.' Discounts are recommended across the board for the 2024 vintage up to 45% in Asia. Unanimously the industry knows that prices must drop in order to interest younger people to try wine in the first place, after boom years when the previous X generation (and part of the Y) boosted expectations that wine would increasingly be the drink of choice for decades to come. The result of that boost was that Bordeaux raised its prices, not just for the prestigious premier crus but for those below them. The consensus within the trade said that prices for the Asian market may have to be discounted 45%. BORDEAUX, FRANCE - SEPTEMBER 22: (NO UK Sales For 28 Days Post Create Date) King Charles III and ... More Queen Camilla do wine tasting during a visit Chateau Smith Haut Lafitte to learn about sustainable vineyard practices in the Bordeaux wine producing region. (Photo by Samir Hussein - Pool/WireImage) Merchants are recommending wine events that will draw in young people, though their numbers wouldn't really add up to much. Others suggest that wine tourism should be promoted, and that labels should be modernized, as German wine producers did a decade ago when they got rid of the old stylized Fraktur fonts better suited for a novel by Goethe. Interestingly enough, while Bordeaux sales languish, Burgundy's are up 16%, according to the Bourgogne Wine Board (BWB), with the U.S. share totaling 20.9 million bottles in 2024, an increase of 15.9% compared to 2023, representing 17.2% of Burgundy's revenue, with Chablis and Mâcon leading the pack. Silver linings aside, the report, which came out in April, does not treat of the Trump tariffs situation, which, after a threat of 200%, dictates a universal tariff of 10%, 20% on wines from France, Italy, Germany and Spain, and 30% on South African. The fall-out from those tariffs has yet to be fully felt. Winemakers have taken to saying their prayers in the vineyards.

News24

44 minutes ago

• News24

Billionaire baby daddy promises to split his $14 billion fortune among his 106 kids

Last year Russian-born billionaire Pavel Durov made headlines when he announced on Telegram, the messaging platform he co-created, that he's the biological father of no fewer than 106 children. Pavel (40), who says he is unmarried and prefers to live alone, has six of his children who were fathered naturally with three different partners, and 100 who were conceived through his prolific sperm donations and live in 12 different countries. The tech tycoon recently told French political magazine Le Point that he is going to leave his fortune, estimated at almost $14bn (R256bn) to all of his children. 'They are all my children and will all have the same rights. I don't want them to tear each other apart after my death,' he told Le Point. He sees no difference whether his children came 'naturally' or 'from my sperm donations'. Each child is set to receive $1.3bn (R23.9bn) when they gain access to their inheritance. However, there's a slight catch – 'I decided my children wouldn't have access to my fortune until a period of 30 years has elapsed, starting from today,' he said last week. He told the publication he wants his offspring to 'live like normal people, to build themselves up alone, to learn to trust themselves, to be able to create, not to be dependent on a bank account'. Pavel first donated his sperm 15 years ago to help out a friend and then decided to donate more widely after learning there was 'a lack of high-quality donor material'. 'The clinic, where I started donating sperm 15 years ago to help a friend, told me more than 100 babies had been conceived this way in 12 countries,' he told Le Point. View this post on Instagram A post shared by Pavel Durov (@durov) He decided to allocate his estate now because his 'work involves risks,' he said, apparently referring to the legal issues he faces over Telegram. Last year French authorities charged him with allegedly being complicit in running a platform in which illegal activity – such as child sex abuse material, drug trade and fraud – could thrive. He has denied the allegations, calling them 'absurd'. 'Just because criminals use our messaging service among many others doesn't make those who run it criminals,' he told the magazine.